Abstract
Gastric cancer is the fourth most common cancer in the world and second most common reason for cancer related death. Projections for the future predict that gastric cancer incidence will continue to rise. Risk factors for gastric cancer are Helicobacter pylori (H pylori) infection, host genetic factors and environmental factors. H pylori is a class I carcinogen and responsible for 60 % - 80 % of all gastric cancers of intestinal and diffuse type, as well as gastric MALT lymphoma.
From animal and intervention studies we know that premalignant gastric lesions development and gastric cancer can be prevented with early H pylori eradication. In countries with gastric cancer incidence higher than 20 / 100 000 per year national screening for H pylori infection and eradication of all H pylori infections should be performed. Type of eradication therapy depends on local antimicrobial resistance rates. Quadruple bismuth or non- bismuth therapies can achive more than 90 % eradication rate. The success of eradication therapy must be controlled with noninvasive test.
Patients with extensive preneoplastic changes (atrophy, intestinal metaplasia) should have endoscopic and histologic controls. Endoscopic screening should be performed in intervals according to the risk stratification by OLGA / OLGIM staging system or A-D staging system.
In countries with high gastric cancer incidence national screening with serological tests for pepsinogen I (PGI), PGI/PGII ratio and H pylori antibodies can select patients at higher risk for gastric cancer.
Keywords: Gastric cancer, Helicobacter pylori, population based screening, therapy, endoscopic surveillance.
Current Pharmaceutical Design
Title:Population Based Helicobacter pylori Screening and Eradication: Advances Versus Side Effects
Volume: 20 Issue: 28
Author(s): Prof Bojan Tepes
Affiliation:
Keywords: Gastric cancer, Helicobacter pylori, population based screening, therapy, endoscopic surveillance.
Abstract: Gastric cancer is the fourth most common cancer in the world and second most common reason for cancer related death. Projections for the future predict that gastric cancer incidence will continue to rise. Risk factors for gastric cancer are Helicobacter pylori (H pylori) infection, host genetic factors and environmental factors. H pylori is a class I carcinogen and responsible for 60 % - 80 % of all gastric cancers of intestinal and diffuse type, as well as gastric MALT lymphoma.
From animal and intervention studies we know that premalignant gastric lesions development and gastric cancer can be prevented with early H pylori eradication. In countries with gastric cancer incidence higher than 20 / 100 000 per year national screening for H pylori infection and eradication of all H pylori infections should be performed. Type of eradication therapy depends on local antimicrobial resistance rates. Quadruple bismuth or non- bismuth therapies can achive more than 90 % eradication rate. The success of eradication therapy must be controlled with noninvasive test.
Patients with extensive preneoplastic changes (atrophy, intestinal metaplasia) should have endoscopic and histologic controls. Endoscopic screening should be performed in intervals according to the risk stratification by OLGA / OLGIM staging system or A-D staging system.
In countries with high gastric cancer incidence national screening with serological tests for pepsinogen I (PGI), PGI/PGII ratio and H pylori antibodies can select patients at higher risk for gastric cancer.
Export Options
About this article
Cite this article as:
Tepes Bojan Prof, Population Based Helicobacter pylori Screening and Eradication: Advances Versus Side Effects, Current Pharmaceutical Design 2014; 20 (28) . https://dx.doi.org/10.2174/13816128113196660733
DOI https://dx.doi.org/10.2174/13816128113196660733 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Time Recall; Future Concept of Chronomodulating Chemotherapy for Cancer
Current Pharmaceutical Biotechnology Corneal Neovascularization: Molecular Events and Therapeutic Options
Recent Patents on Inflammation & Allergy Drug Discovery Src Family Kinases: Potential Targets for the Treatment of Human Cancer and Leukemia
Current Pharmaceutical Design Protective Effects of Low Dose Vorinostat on Cisplatin-Induced Nephrotoxicity in Rats
Current Molecular Pharmacology Evaluation of the Diagnostic Properties of Serum hsa-miR-223-5p in the Detection of Gastric Cancer: A Case-Control Study
Anti-Cancer Agents in Medicinal Chemistry Clinical and Translational Research Challenges in Biliary Tract Cancers
Current Medicinal Chemistry Intracellular Drug Delivery: Mechanisms for Cell Entry
Current Pharmaceutical Design Histone Modifier Differentially Regulates Gene Expression and Unravels Survival Role of MicroRNA-494 in Jurkat Leukemia
MicroRNA 4-Anilinoquinazoline Derivatives with Epidermal Growth Factor Receptor Inhibitor Activity
Anti-Cancer Agents in Medicinal Chemistry Physical and Structural Stability of the Monoclonal Antibody, Trastuzumab (Herceptin®), Intravenous Solutions
Current Pharmaceutical Biotechnology Multimodal HDAC Inhibitors with Improved Anticancer Activity
Current Cancer Drug Targets Management of Glioblastoma Multiforme by Phytochemicals: Applications of Nanoparticle-Based Targeted Drug Delivery System
Current Drug Targets Curious (Old and New) Antiviral Nucleoside Analogues with Intriguing Therapeutic Potential
Current Medicinal Chemistry The Long Term Biological Consequences of Anorexia Nervosa
Current Nutrition & Food Science COVID-19 Invades Several Important Organs other than the Lungs: Organs Crosstalk
Coronaviruses Pharmacological Treatment of Cognitive Symptoms in Major Depressive Disorder
CNS & Neurological Disorders - Drug Targets Gene Therapy (Part II)
Current Gene Therapy Recent Advances in the Synthesis and Anticancer Activity of Some Molecules Other Than Nitrogen Containing Heterocyclic Moeities
Mini-Reviews in Medicinal Chemistry Risk Assessment and Regulation of Molecular Farming - A Comparison between Europe and US
Current Pharmaceutical Design Vitamin E - Occurrence, Biosynthesis by Plants and Functions in Human Nutrition
Mini-Reviews in Medicinal Chemistry